Literature DB >> 17979493

Transformation of polycythemia vera to chronic myelogenous leukemia.

Imran Mirza1, Christine Frantz, Gwendolyn Clarke, Arnold J Voth, Robert Turner.   

Abstract

Transformation of polycythemia vera to chronic myelogenous leukemia is a rare event. We report 2 women with long-standing polycythemia vera who developed chronic myelogenous leukemia. Both patients had no BCR/ABL1 fusion at the time of polycythemia vera diagnosis but were positive for the fusion at chronic myelogenous leukemia onset. Most patients with polycythemia vera have JAK2(V617F) mutation. Analysis of an archival bone marrow aspirate sample from 1 patient showed a heterozygous mutation status. The blood and bone marrow samples from the other patient showed the presence of homozygous JAK2(V617F) mutation and BCR/ABL1 fusion. The possible pathogenesis of such an event is discussed in the light of current literature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979493     DOI: 10.5858/2007-131-1719-TOPVTC

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

Review 1.  [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].

Authors:  K Hussein; G Büsche; J Schlue; U Lehmann; H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 2.  Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.

Authors:  Shinsuke Mizutani; Junya Kuroda; Daisuke Shimizu; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-02-11       Impact factor: 2.490

3.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

4.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

5.  Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.

Authors:  Gholamreza Toogeh; Shirin Ferdowsi; Fatemeh Naadali; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Reza Shirkoohi; Seyed H Ghaffari
Journal:  Med Oncol       Date:  2010-05-25       Impact factor: 3.064

Review 6.  Chronic Myeloid Leukemia: Beyond BCR-ABL1.

Authors:  Ting Zhou; L Jeffrey Medeiros; Shimin Hu
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 7.  Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

Authors:  Gilbert Bader; Bernard Dreiling
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

8.  Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera.

Authors:  Mariana Lorenzo; Sofia Grille; Mariana Stevenazzi
Journal:  J Hematol       Date:  2020-04-23

9.  Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Dae-Young Kim; Je-Hwan Lee; Kyoo-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.